Non-invasive profiling of KRAS mutations in lung cancer using droplet digital polymerase chain reaction
Monaldi Archives for Chest Disease · 2025
DOI: 10.4081/monaldi.2025.3190 ↗Kurz gefasst
Fachartikel in der Zeitschrift Monaldi Archives for Chest Disease, 2025. Verfasst von Reena Kishore und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Genetics and Cancer, Nitte University Centre for Science Education and Research, Nitte (Deemed to be University), Deralakatte…. Hauptthemen laut MEDLINE: Lung Neoplasms, Proto-Oncogene Proteins p21(ras), Polymerase Chain Reaction. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
With rising cases of lung cancer worldwide, liquid biopsies are becoming increasingly popular as clinically relevant potential non-invasive alternatives to tissue-based biopsies. The principle of partitioning utilized by the droplet digital polymerase chain reaction (ddPCR) makes it a highly sensitive technique for detecting rare tumor-derived mutations in blood. The presence of KRAS mutations is a negative prognostic marker for tyrosine kinase inhibitor (TKI) therapy in lung cancer; hence, profiling of major KRAS mutations before treatment is very crucial for the success of TKI therapy. This study was aimed at profiling three major KRAS mutations, namely G12D (GGT→GAT), G12V (GGT→GTT), and G13D (GGC→GAC) in lung cancer patients using ddPCR. ddPCR assays that rely on probe-based chemistry were standardized for KRAS G12D, KRAS G12V, and KRAS G13D mutations using cfDNA extracted from the patient’s blood. To determine the concordance, blood-derived cfDNA and tumor DNA were compared using ddPCR. A positivity rate of 81.67% for KRAS mutations was observed in the cohort analyzed. KRAS mutations in the cfDNA from blood were effectively detected by ddPCR even at low fractional abundance. Moreover, a comparison of blood-derived cfDNA and tumor-derived genomic DNA-based analysis revealed a concordance of 66.67%, suggesting tumor heterogeneity as the probable reason for the lack of total concordance between the data. This study highlights the usefulness of ddPCR as a prospective clinical tool in oncology and liquid biopsy using blood cfDNA. It can be considered a better alternative to tissue biopsies and mutation profiling of candidate genes, particularly those that are linked to therapeutic response to TKIs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Genetics and Cancer, Nitte University Centre for Science Education and Research, Nitte (Deemed to be University), Deralakatte, Mangaluru, Karnataka.
- Department of Respiratory Medicine, Yenepoya Medical College Hospital, Mangalore, Karnataka.
- Department of Translational Molecular Pathology, MD Anderson Cancer Center, Houston, Texas.
- Department of Pulmonary Medicine, KS Hedge Medical Academy, Nitte (Deemed to be University), Deralakatte, Mangaluru, Karnataka.
ORCID-Profile: Reena Kishore, Sonam N Kille, Rhea Kishore
Zitieren
APA
Kishore, R., Kille, S. N., Kishore, R., Venkataram, R., Arjuna, S., Chakraborty, G., Hosmane, G. B., & Chakraborty, A. (2025). Non-invasive profiling of KRAS mutations in lung cancer using droplet digital polymerase chain reaction. Monaldi Archives for Chest Disease. https://doi.org/10.4081/monaldi.2025.3190
Vancouver
Kishore R, Kille SN, Kishore R, Venkataram R, Arjuna S, Chakraborty G, et al. Non-invasive profiling of KRAS mutations in lung cancer using droplet digital polymerase chain reaction. Monaldi Archives for Chest Disease. 2025. doi:10.4081/monaldi.2025.3190
BibTeX
@article{Kishore2025,
author = {Kishore, Reena and Kille, Sonam N and Kishore, Rhea and Venkataram, Rajesh and Arjuna, Srividya and Chakraborty, Gunimala and Hosmane, Giridhar B and Chakraborty, Anirban},
title = {Non-invasive profiling of KRAS mutations in lung cancer using droplet digital polymerase chain reaction},
journal = {Monaldi Archives for Chest Disease},
year = {2025},
doi = {10.4081/monaldi.2025.3190}
}
EUVIMED